Patents by Inventor Lawrence S. Melvin, Jr.

Lawrence S. Melvin, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20170196844
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: January 23, 2017
    Publication date: July 13, 2017
    Inventors: MICHAEL GRAUPE, Keith Koch, Britton Kenneth Corkey, Gregory Notte, Lawrence S. Melvin, JR.
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: 9586932
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: March 7, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Keith Koch, Britton K. Corkey, Gregory Notte, Lawrence S. Melvin, Jr.
  • Rapamycin for the Treatment of Lymphangioleiomyomatosis
    Publication number: 20160235668
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: October 7, 2014
    Publication date: August 18, 2016
    Inventors: Jonathan M. Rothberg, Henri Lichenstein, Thomas Armer, Lawrence S. Melvin, JR.
  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20160130251
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: May 19, 2015
    Publication date: May 12, 2016
    Inventors: Michael Graupe, Keith Koch, Britton K. Corkey, Gregory Notte, Lawrence S. Melvin, JR.
  • RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS
    Publication number: 20150265582
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: February 10, 2015
    Publication date: September 24, 2015
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: 9067933
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: June 30, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Kenneth Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte
  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20140018370
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: July 2, 2013
    Publication date: January 16, 2014
    Inventors: Britton Kenneth Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, JR., Gregory Notte
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: 8598360
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 3, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: 8552196
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 8, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: 8378108
    Abstract: The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: February 19, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte
  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20130035339
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Applicant: Gilead Sciences, Inc
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, JR., Gregory Notte
  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20130012521
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, JR., Gregory Notte
  • Metabolites and derivatives of ambrisentan
    Patent number: 8217155
    Abstract: The invention relates to derivatives and metabolites of ambrisentan, including compounds of general Formula (I) or salts, hydrates, solvates, racemates, or optical isomers thereof, wherein R1 is —OH or —OCH3; R2 is —H, lower alkyl (e.g. C1-C4 alkyl) or glycosidyl; and R3 and R4 are independently —CH3, —C(O)H or —CH2OR6, wherein R6 is —H or a hydrocarbyl group having 1 to 20 carbon atoms.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: July 10, 2012
    Assignees: Gilead Colorado, Inc., Abbott GmbH & Co. KG
    Inventors: Lawrence S. Melvin, Jr., Martina Ullrich, Hans-Guenther Hege, Jürgen Weymann
  • Cycloalkylidene and heterocycloalkylidene inhibitor compounds
    Patent number: 8198299
    Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: June 12, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Lawrence S. Melvin, Jr., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
  • Fused heterocyclyc inhibitor compounds
    Patent number: 8124764
    Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: February 28, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Lawrence S. Melvin, Jr., Michael Graupe, Chandrasekar Venkataramani
  • CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS
    Publication number: 20120045412
    Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Application
    Filed: October 28, 2011
    Publication date: February 23, 2012
    Applicant: Gilead Sciences, Inc.
    Inventors: Lawrence S. Melvin, JR., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
  • Cycloalkylidene and heterocycloalkylidene inhibitor compounds
    Patent number: 8088771
    Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: January 3, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Lawrence S. Melvin, Jr., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
  • IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS
    Publication number: 20110052527
    Abstract: A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Application
    Filed: November 10, 2010
    Publication date: March 3, 2011
    Applicant: Gilead Sciences, Inc.
    Inventors: Lawrence S. Melvin, JR., Michael Graupe, Chandrasekar Venkataramani
  • APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS
    Publication number: 20110009410
    Abstract: The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Application
    Filed: July 12, 2010
    Publication date: January 13, 2011
    Applicant: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, JR., Gregory Notte
  • BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS
    Publication number: 20100292320
    Abstract: The present disclosure provides a compound of general Formula (I) having enzyme inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
    Type: Application
    Filed: December 12, 2008
    Publication date: November 18, 2010
    Applicant: Gilead Colorado, Inc.
    Inventor: Lawrence S. Melvin, JR.